Desarrollo y optimización del gel proniosomal que contiene etodolaco: evaluación in vitro, ex vivo e in vivo by Patil, Moreshwar et al.




Development and Optimization of 
Proniosomal Gel Containing Etodolac: In-
vitro, Ex-vivo and In-vivo Evaluation
Desarrollo y optimización del gel proniosomal que 
contiene etodolaco: evaluación in vitro, ex vivo e 
in vivo
Moreshwar Patil1 orcid 0000-0002-8060-1687
Prashant Pandit2 orcid 0000-0003-1458-9381
Pavan Udavant3 orcid 0000-0001-6870-7852
Sandeep Sonawane4 orcid 0000-0002-4858-7651
Deepak Bhambere5 orcid 0000-0002-7880-9606
1,2,5Savitribai Phule Pune University, Pune, Department of Pharmaceutics, MET’s Institute of Pharmacy, Nashik 
422 003, India.
3Savitribai Phule Pune University. Department of Pharmacology, MET’s Institute of Pharmacy, Nashik 422 003, 
Pune, India.
4Savitribai Phule Pune University Department of Pharmaceutical analysis, MET’s Institute of Pharmacy, Nashik 








This work has not been financially funded by any funding agency
Conflict of interest
The authors declare no conflict of interest.
Ars Pharm. 2021;62(3):290-304 290
Resumen
Introducción: Etodolac se usa en el tratamiento del dolor agudo y la inflamación. Tiene baja solubilidad debido a 
la alta hidrofobia y se informa que tras la administración oral muestra alteraciones gástricas. Esto fomenta el desar-
rollo de formulación tópica en lugar de oral.
Método: En este trabajo utilizamos el método de separación de fase de coacervación para el desarrollo del sistema 
vesicular cargado con etodolaco mediante el uso de tensioactivos no iónicos, colesterol y lecitina de soja. El diseño 
central compuesto (rotativo) se utilizó para optimizar las concentraciones de lecitina de soja, surfactante y colester-
ol. Las formulaciones preparadas se caracterizaron por análisis de tamaño de vesículas, potencial zeta, eficiencia de 
atrapamiento, permeación in vitro, permeación ex vivo y estudio antiinflamatorio.
Resultados: Etodolac quedó atrapado con éxito en todas las formulaciones que tenían una eficiencia en el intervalo 
de 74,36% a 90,85%, siendo mayor a 4 ° C que a temperatura ambiente. Cuando se hidrata con agua, los niosomas 
se producen espontaneamente el rango de 54 a 141 (por mm cúbico). Los resultados del estudio de difusión in vitro 
revelaron que el etodolaco se liberó en un rango de 71,86 a 97,16% durante un período de 24 horas. El tamaño me-
dio de vesícula de la formulación optimizada se encontró en 211,9 nm con un PDI de 0,5. Las respuestas observadas, 
es decir,% de eficacia de encapsulación y liberación de fármaco, fueron 74,12 y 95,08 respectivamente. El potencial 
zeta fue de -19,4 mV y reveló la estabilidad de la formulación, que fue confirmada adicionalmente por la ausencia de 
cambios en el contenido del fármaco y la liberación del fármaco después de los estudios de estabilidad. El% de in-
hibición en el volumen de la pata fue del 40,52% y del 43,61% para la prueba y el gel proniosómico comercializado.
Conclusión: la formulación de gel proniosomal fue estable y podría mejorar el suministro de etodolaco a la piel 
debido a la excelente capacidad de permeación del sistema vesicular.
Palabras clave:administración de fármacos vesiculares; gel proniosómico; etodolaco; tensioactivos no iónicos; es-
tudio antiinflamatorio.
Abstract
Introduction: Etodolac is used in the treatment of acute pain and inflammation. It has low solubility because of 
high hydrophobicity and it is reported that upon oral administration shows gastric disturbances. This encourages 
the development of topical vesicular formulation.
Method: In this work we used coacervation-phase separation method for the development of etodolac loaded ve-
sicular system by using non-ionic surfactants, cholesterol and soya lecithin. Central composite design (rotatble) was 
used to optimize the concentrations of soy lecithin, surfactant and cholesterol. The prepared formulations were 
characterized by number of vesicles formed, vesicle size, zeta potential, entrapment efficiency, in-vitro permeation, 
ex-vivo permeation and anti-inflammatory study.
Results: Etodolac was successfully entrapped in all formulations having efficiency in the range of 74.36% to 90.85%, 
which was more at 4 °C than room temperature. When hydrated with water; niosome in the range of 54 to 141 (per 
cubic mm) were spontaneously produced. The results of in-vitro diffusion study revealed that etodolac was released 
in the range of 71.86 to 97.16% over a period of 24 hrs. The average vesicle size of optimized formulation was found 
211.9 nm with PDI of 0.5. The observed responses i.e. % encapsulation efficiency and drug release were 74.12 and 
95.08 respectively. The zeta potential was -19.4mV revealed the stability of formulation which was further confirmed 
by no changes in drug content and drug release after stability studies. The % inhibition in paw volume was 40.52% 
and 43.61% for test and marketed proniosomal gel.
Conclusion: Proniosomal gel formulation was stable and could enhance skin delivery of etodolac because of excel-
lent permeation capability of vesicular system.
Keywords:Vesicular drug delivery; proniosomal gel; etodolac; non-ionic surfactants; anti- inflammatory study.
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Highlights
• Topically applied drugs can be delivered as proniosomal vesicular system.
• Vesicular system can be used to increase the penetrability of the drug.
• Span, soy lecithin and cholesterol can be used to develop stable formulation.
• Statistical technique like central composite design would be helpful in formulation optimization.
Introduction
Non-steroidal anti-inflammatory drugs (NSAIDs) are frequently prescribed for arthritis, low back pain 
and some joint diseases(1). The well reported mechanism of action is reversible inhibition of cycloo-
xygenase enzyme (COX) and decrease the synthesis of prostaglandins. However, due to inhibition of 
prostaglandins (PGs) which protects the gastric mucosa, they show side effects including dyspepsia to 
peptic ulcer and gastrointestinal haemorrhage. NSAIDs are acidic in nature they may produce local irri-
tation and lesions on the gastrointestinal mucosa. Hence, some of the NSAIDs are administered percu-
taneously and transdermally to achieve local or systemic effect as an alternative to oral and parenteral 
administration(2). However, the barrier layer i.e. stratum corneum prevents the penetration of the drugs 
to lower layers of the skin and/or to enter systemic circulation. In this context, the formulation plays a 
key role in the penetration and absorption of the active ingredient.
Etodolac is BCS Class II drug. It is a selective COX-2 inhibitor with 10-fold COX-2 selectivity over COX-1; 
therefore, it can be prescribed safely for the treatment of acute pain and inflammation. It has poor 
water solubility (75 µg/ml) because of high hydrophobicity(3). It causes gastric irritation, constipation, 
diarrhoea, vomiting, headache dizziness, sore throat and blurred vision(4) and may create limitation in 
formulation of oral dosage forms. By considering the drawbacks of oral delivery of etodolac; it would 
beneficial to give it through topical route using novel vesicular drug delivery system. It was reflected 
from the literature that niosomes; a vesicular system could be beneficial for topical and transdermal 
delivery because they act as a reservoir of drug for a prolonged period of time and enhance skin pene-
tration(5,6) and thus increases bioavailability. However the niosomes are also has instability issues like 
fusion, aggregation, sedimentation and leakage of entrapped drug. These mentioned problems can be 
avoided by using non ionic surfactant formulation which is anhydrous, free flowing i.e. proniosomes 
and can form vesicles after hydration (niosomes). Proniosomes can entrap both hydrophilic and lipo-
philic drugs. Proniosomal gel is beneficial to reduce drugs associated side effects, increase effective-
ness and make the formulation physically stable. In this context we had considered development of 
vesicular topical formulation with optimal quality in short period of time with less number of exper-
imental trials using varying proportion of soy lecithin, cholesterol and non-ionic surfactant(7). Hence, 
two level three factor rotatable central composite design (CCD) was used study the effect of amount of 
soy lecithin, non ionic surfactant and cholesterol on entrapment efficiency (%EE) and % drug release.
Materials and Methods
Materials
Etodolac was received as a gift sample from Swiss Garnier Life Sciences, Una, Himachal Pradesh, India. 
Lipoid S 100 and Phospholipon 80H were obtained from Ludwings Shafen, Germany. Span (20, 40 and 
60) was purchased from S. D. Fine Chem. Ltd., Mumbai, India. Cholesterol was obtained from Thomas 
Baker Ltd., Mumbai, India. All other chemicals used in this study were of analytical grade.
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To eliminate the possibility of interaction between etodolac and cholesterol, lecithin and Span, com-
patibility study was carried out by storing the physical mixture (1:1) in the stability chamber at 40 
°C/75% RH for 1 month. At the end of the study, FT-IR spectrums of etodolac alone and binary mixture 
were recorded and studied.
Prior incorporation of etodolac, trial formulation batches containing varying proportions of Span (20, 
40 and 60): lecithin (Lipoid S 75, Phospholipon 80 H, Lipoid S 100) in ratio of 0.5:1, 1:1, 1:0.5 and 1:0.75 
were developed. These preparations were observed for homogeneity, consistency, clogging and sud-
den change in viscosity.
Development of proniosomal gel
Etodolac proniosomes were prepared by modified coacervation phase separation method reported 
by Thakur et. al(8). Briefly, etodolac (5% w/w) and varying concentrations of Span 60, Lipoid S 100 and 
cholesterol were mixed with 2.5 ml of absolute ethanol in a wide mouth glass tube. The ingredients 
were mixed together; open end of the glass tube was covered and warmed on a water bath at 60-70 ºC 
for about 5 min. Phosphate buffer saline (pH 7.4) was added and warmed on a water bath for ≈2 min-
utes to form dispersion. The mixture was allowed to cool to room temperature until the dispersion was 
converted to proniosomes having semisolid consistency and stored in dark until further use.
Optimization by design of experiment
A full central composite design (rotatable) was used in this study. Design matrix is given in Table 1. The 
amount of Span 60 (A), Lipoid S 100 (B) and cholesterol (C) were taken as independent variables, while 
% entrapment efficiency (Y1) and % drug release (Y2) were taken as dependent variables. The factors 
were studied at 2 levels (−1, +1) indicating low and high respectively. The design consisted of three 
groups of design points, including two level three factor factorial design points, axial or star points 
and center points. Total 20 experiments consisting of 8 factorial points, 6 axial points, and 6 replicated 
central points were performed according to the central composite design matrix generated by Design 
Expert V. 11 Software (Table 2) (Stat-Ease, Minneapolis, USA).
Table 1: Two level three factor central composite design
Factor Low level High level -α +α
Experimental domain (Coded values)
Span 60 (mg) -1 +1 -1.682 +1.682
Lipoid S 100 (mg) -1 +1 -1.682 +1.682
Cholesterol (mg) -1 +1 -1.682 +1.682
Experimental domain (Actual values)
Span 60 (mg) 1200 1800 995.46 2004.5
Lipoid S 100 (mg) 500 1000 329.55 1170
Cholesterol (mg) 50 100 32.96 117.04
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Table 2: Experimental design batches of proniosomes
Experiment Span 60(mg) Lipoid S 100 
(mg)
Cholesterol (mg) Ethanol(ml) Saline sol.
(ml)
Factorial designs
CD 1 1200 500 50 2.5 1.8
CD 2 1800 500 50 2.5 1.8
CD 3 1200 1000 50 2.5 1.8
CD 4 1800 1000 50 2.5 1.8
CD 5 1200 500 100 2.5 1.8
CD 6 1800 500 100 2.5 1.8
CD 7 1200 1000 100 2.5 1.8
CD 8 1800 1000 100 2.5 1.8
Star design
CD 9 995.46 750 75 2.5 1.8
CD 10 2004.5 750 75 2.5 1.8
CD 11 1500 329.55 75 2.5 1.8
CD 12 1500 1170.45 75 2.5 1.8
CD 13 1500 750 32.96 2.5 1.8
CD 14 1500 750 117.04 2.5 1.8
Center points
CD 15 1500 750 75 2.5 1.8
CD 16 1500 750 75 2.5 1.8
CD 17 1500 750 75 2.5 1.8
CD 18 1500 750 75 2.5 1.8
CD 19 1500 750 75 2.5 1.8
CD 20 1500 750 75 2.5 1.8
Evaluation of proniosomal gel
Determination of pH and viscosity
The pH of all formulations was determined by using pH meter at ambient temperature. The pH meter 
was calibrated before each use. About 1g of gel was dissolved in 25ml of distilled water and pH was 
measured by immersing the electrode. The viscosities of different proniosomal gel formulation were 
determined at 25°C using a Brookfield viscometer. The formulation (more than 5g) was placed in a 
beaker and was allowed to equilibrate for 5 min before measuring the dial reading using a spindle no 
S-64 at 20 rpm(6,9).
% Encapsulation efficiency (%EE)
Approximately 0.2 g of proniosomal gel was dispersed in 10 ml of phosphate buffer (pH 7.4). The dis-
persion was sonicated, centrifuged at 18,000 rpm at -20°Ċ for 30 min. (C-24 BL, Remi lab) to separate 
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unentrapped drug. The supernatant was removed and quantified by an UV spectrophotometer at 278 
nm(10). The % encapsulation was calculated by the following equation:
Where,
Ct is the concentration of total etodolac; Cf is the concentration of free etodolac.
Vesicle size and zeta potential
Vesicle size, size distribution and zeta potential were determined by Malvern Zetasizer in order to as-
certain the stability as well as the reproducibility of the method. About 1g of gel was dissolved in 20 ml 
double distilled water and agitated to get homogeneous dispersion. Mean globule diameter and zeta 
potential was recorded(11).
Rate of Spontaneity
This test helps to determine the numbers of niosomes formed spontaneously after hydration in 15-20 
min. Approximately 100 or 200 mg of proniosomal gel was transferred to glass bottle and spread uni-
formly around walls. About 20ml of saline solution was added along the walls and was left aside for 20 
min. then a drop was withdrawn and place on Neubauers chamber to count the number of vesicles(12).
In-vitro and Ex-vivo drug release
In-vitro release study was performed by using diffusion cell apparatus and egg membrane. Egg mem-
brane was separated by putting the egg shell in mixture of water and hydrochloric acid in which the 
shell is dissolved to calcium chloride with effervescence of carbon dioxide. Before initiation of study; 
the egg membrane was soaked in phosphate buffer for 24 hours. About 1g of proniosomal gel was 
placed in the donor compartment tube and spread over the egg membrane which was clamped at the 
end of the tube. The acceptor compartment consists of phosphate buffer (pH 7.4). The entire surface of 
the cell was in contact with the medium present in the receptor compartment which was agitated by 
magnetic stirrer at rpm 600 and temperature 32±1°Ċ. A sample was removed at specific time interval 
for up to 24 h with same amount replaced to maintain sink condition. The sample was analysed at 278 
nm against blank using UV spectrophotometer. For ex-vivo study; the egg membrane was replaced by 
excised skin of abdominal region of rat. The stratum corneum of the skin faced the drug donor com-
partment whereas dermis faced the receiver compartment(13-16).
Scanning electron microscopy
The surface morphology of the formulation was determined by placing the drop of niosome dispersion 
on carbon coated grid, vacuum dried and observed microscopically at an accelerating voltage of 10 Kv 
using scanning electron microscope (JEOL/JEM 2100, Japan).
Anti-inflammatory study
The study protocol was approved by the Animal Ethical Committee of MET’S Institute of Pharmacy 
(CPCSEA Reg. no-1344/ac/10/CPCSEA/IAEC) and it was conducted as per the guidelines. Fifteen albino 
mice were selected. They were divided into 3 groups (control, standard and test) each containing 5 
animals and kept fasted overnight. About 0.1ml of 1 % (w/v) carrageenan was injected on the left hind 
paw to induce edema. Control group received carrageenan (1% w/v) only while standard and test were 
treated with marketed and developed proniosomal gel in addition to carrageenan. The paw thickness 
was measured using vernier calliper at the time interval of 0, 30, 60, 120 and 180 minute. The % inhi-
bition of diameter paw edema by proniosomal gel and marketed gel treated group compared with 
carrageenan control group(17). From the mean edema volume, the percentage inhibition of the edema 
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was calculated between the treated and control groups. Before anti-inflamatory activity skin irritation 
study was conducted to find out the allergic potential of formulation.
Where,
Vc = Paw volume of control
Vt = Paw volume of test
Vs = Paw volume of standard
Results and Discussion
Preformulation study
The FT-IR spectrums of etodolac, etodolac with Span 60, Lipoid S-100 and cholesterol are shown in Fig-
ure 1. The principle peaks of the etodolac i.e. –NH stretching at 3342.64 cm-1, -CH stretching in alkane 
at 2970.38 cm-1 and –CO stretching in ketone at 1745 cm-1, –CO stretching in aromatic at 1261 cm-1 were 
present in all physical mixtures. There was neither deletion of existing peak nor addition of new peak 
in the spectrum revealed the compatible nature of the excipients with etodolac. Hence; by using these 
materials stable formulations were developed.
Figure 1. FTIR spectrums for prediction of incompatibility: etodolac and its binary mixture with Span 60, Lipoid S 
100 and cholesterol.
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Preliminary studies have demonstrated that formulations of Span 20 and 40 with Lipoid S 100 and 
Phospholipon 80 H were transparent; yellow and semisolid. Gels of Span 40 had shown clogging with 
change in viscosity after 1 week of storage. In case of Span 20, formulations were stable but less amount 
of etodolac was incorporated. Hence; it would be beneficial to use Span 60 as it had shown high entrap-
ment efficiency in addition to consistency. Similarly niosome vesicles prepared with Lipoid S 100 were 
observed good and denser than prepared with Phospholipon 80 H.
Data analysis by central composite design
Effect of composition variable on %EE
Proniosomes are made of lipidic materials and considered as it has ability to entrap drug. The response 
(Y1) i.e. %EE was ranged from 74.36±0.22 to 90.85±0.26 (Table 3). ANOVA test revealed that the response 
surface quadratic model was significant. The polynomial equation for encapsulation efficiency is
%EE=+81.42-1.58*A-2.35*B+1.75*C-2.19*A*B-2.30*A*C+0.96*B*C-0.88A2-0.13B2+0.90C2
It was observed from the equation and perturbation plot (Figure 2) that the amount of Span 60 and 
Lipoid S 100 had negative effect on encapsulation while amount of cholesterol had positive effect in-
dicating that increase in concentration of cholesterol encapsulate more amount of drug. It may be 
due to the fact that cholesterol forms hydrogen bond with non ionic surfactant and impart stability to 
niosomes and hence, more amount of drug is encapsulated(18). It is reported that Span 60 has HLB value 
of 4.7 and decreased HLB value is also responsible for decreases encapsulation efficiency than that of 
surfactant with high HLB(19).
Table 3: Results of responses measured for 20 CCD batches




CD 1 80.85±0.19 74.8±0.94
CD 2 89.31±0.32 84.17±0.65
CD 3 80.18±0.31 71.86±0.43
CD 4 76.89±0.12 95.4±0.64
CD 5 84.75±0.24 90.53±0.84
CD 6 81.03±0.34 90.9±0.89
CD 7 84.94±0.16 85.47±0.51
CD 8 75.46±0.18 96.06±0.14
CD 9 82.42±0.24 85.01±0.72
CD 10 74.36±0.22 97.16±0.69
CD 11 84.59±0.15 90.9±0.5
CD 12 76.48±0.28 95.63±0.94
CD 13 76.01±0.37 82.1±0.63
CD 14 90.85±0.26 80±0.66
CD 15 81.2±0.23 87.3±0.35
CD 16 81.37±0.27 86.76±0.83
CD 17 81.76±0.33 85.3±0.45
CD 18 81.23±0.28 84.15±0.81
CD 19 81.66±0.35 86.13±0.34
CD 20 81.46±0.16 87.46±0.81
Optimized 83.74±0.72 86.62±0.85
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Figure 2. Perturbation plot for % encapsulation efficiency (EE).
Effect of composition variable on % drug release
The percentage cumulative drug release was observed in the range of 71.86±0.43 to 97.16±0.69 (Table 
3). Following is the polynomial equation for %CDR:
% CDR= +86.26+4.71*A+1.20*B+2.43*C+3.05*A*B-2.74*A*C-1.02*B*C+1.21*A2+1.99*B2-2.33*C2
The component of formulation; Span 60, Lipoid S 100 and cholesterol had positive coefficients. The 
perturbation plot (Figure 3) reveled that curvature of factor A i.e. Span 60 demonstrated significant 
proportional effect on drug release as compare to Lipoid S 100 and cholesterol. It was observed from 
the release profile that the vesicular system prolonged the release of etodolac for 24 hrs. The release 
studies have demonstrated presence of some amount of drug may bind to surface because of that ini-
tial burst release of etodolac followed by slow release was observed. The prolonged release for longer 
period of time could improve patient compliance as it reduces application frequency(20).
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Figure 3. Perturbation plot for % cumulative drug release (CDR).
Statistical evaluation suggested that quadratic model was significant. The release mechanism was 
studied for all formulation and it was observed that it followed zero order release kinetic. The compar-
ative release profiling of optimized formulation and marketed formulation is given in Figure 4.
Figure 4. Comparative release profile of optimized (A) and marketed (B) formulation
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In order to optimize the formulation desirability approach test was used where the goal for the entrap-
ment efficiency was set to 75% to 80% and maximum for %CDR. From the 20 solutions obtained, the 
one solution which has desirability equal to 1 was selected and experiment was conducted in triplicate 
and evaluated for %EE and %CDR. The predicted and observed responses of optimized formulation are 
shown in Table 4.
Table 4: Predicted and observed responses for optimized formulation
Span 60 (mg) 1800 Response Predicted Observed
Lipoid S 100 (mg) 971 EE (%) 75.06 74.12
Cholesterol (mg) 58 CDR (%) 97.22 95.08
Regression analysis of the data is presented in Table 5.
Table 5: Regression analysis of two-level-three-factor central composite design of etodolac loaded proniosomes
Response Model R2 Adjusted R2 Predicted R2 Adequate 
precision
p-value
EE (%) Quadratic 0.7629 0.5495 -0.8165 6.390 0.0299
CDR (%) Quadratic 0.8453 0.7061 -0.1186 8.596 0.0047
Evaluation of proniosomal gel
pH and viscosity
This finding is expected since, topical systems are directly applied on the skin; they should not causes 
skin irritation or disruption of the skin structure. The pH of all formulation batches was in between 
4.2±0.20 to 5.9±0.1 and optimized formulation had 5.6±0.05. Therefore, it was reasonable to expect that 
formulations were found to be compatible with skin pH. The viscosity was related to amount of Span 
60. Batches containing lower batches of Span 60 had low viscosity. The viscosity of optimized formula-
tion was 6686±147.14 cPs which is what one could expect from the gel. All the formulations had shown 
shear thinning properties.
Zeta potential and vesicle size
The zeta potential demonstrates the potential of the parameter for the stability of the colloidal disper-
sions like vesicular formulation. Higher is the value of zeta potential; greater is the repulsion because 
of reduced aggregation between the particles(18,19). The zeta potential of optimized formulation was 
-19.4mV; the negative value was due to negatively charged phospholipids present in soy lecithin. Be-
cause of negative charge; the droplets were repelled away from each other; avoid aggregation and 
impart stability. Another important parameter is size of the vesicle. The average vesicle size of the opti-
mized formulation was found to be 211.9 nm with PDI of 0.58. This revealed that the vesicles had larger 
size and were relatively homogenous. The larger size of the vesicles containing soy lecithin is due to the 
difference in the composition of soy and egg derived lecithin(20).
The rate of spontaneity i.e. formation of vesicles per 1 cubic mm was ranged from 51.25±0.66 to 
141.75±0.62. The optimized formulation had the rate of 94.75±0.54.
Ex-vivo drug release
The formulations were studied using rat’s excised skin and it was observed that the release of drug 
was more than that of marketed gel. Release behaviour justified the significance of vesicular systems. 
It seems that proniosomal formulation can serve as a penetration enhancer by modifying the lipids 
and increasing the fluidity which leads to weakening of skin’s barrier properties(21). The release profile 
is shown in Figure 5.
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Figure 5. Ex-vivo release profile of optimized formulation
SEM study
The SEM analysis enables the determination of surface morphologies like shape and size of pronio-
somes than its hydrated form i.e. niosomes. As illustrated in Figure 6; the photomicrographs indicated 
that the vesicles had size around 200 nm and spherical in shape. The increased size of the vesicle was 
not related to instability issues but may be due to removal of moisture during SEM analysis from the 
preparation causing them to aggregate.
 
Figure 6. SEM photomicrographs of optimized formulation.
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Anti-inflammatory activity
The paw volume of control, standard and test formulation treated animals was measured. The % in-
hibition of paw volume was compared amongst standard and test groups. It was observed that the % 
inhibition by marketed gel and proniosomal gel was 43.61 and 40.52 % respectively which indicates 
that formulated proniosomal gel was as effective as standard gel in its anti-inflammatory activity. The 
results are presented in Figure 7. The P value is<0.0294 is considered as extremely significant by apply-
ing ANOVA test followed by Dunnett test.
Figure 7. Comparative study of anti-inflammatory activity of optimized and marketed formulation.
Conclusion
The work has demonstrated the use of Span 60, Lipoid S 100 (soy lecithin) and cholesterol appropriate 
for the development of etodolac proniosomal gel. The proniosomal gel formulation was stable for the 
period of 3 months. It had proper features for transdermal delivery. The ex vivo study indicated more 
release than marketed formulation; it could be due to increased penetration ability of the vesicular sys-
tem. The anti-inflammatory studies showed that the formulation was comparable with marketed one. 
Thus, the developed topical proniosomal formulation may prove to be a promising carrier for other 
anti-inflammatory drugs too in the context of simple production and scale up.
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